- Report
- March 2025
- 160 Pages
Global
From €4277EUR$4,650USD£3,619GBP
- Report
- December 2024
- 110 Pages
Global
From €5472EUR$5,950USD£4,631GBP
- Report
- May 2025
- 189 Pages
Global
From €5380EUR$5,850USD£4,553GBP
- Report
- July 2024
- 120 Pages
Global
From €4369EUR$4,750USD£3,697GBP
- Report
- August 2019
- 264 Pages
Global
From €3674EUR$3,995USD£3,109GBP
- Report
- January 2021
- 252 Pages
Global
From €4414EUR$4,799USD£3,735GBP
- Report
- December 2021
- 353 Pages
Global
From €5058EUR$5,500USD£4,281GBP
- Report
- March 2023
- 185 Pages
Global
From €4093EUR$4,450USD£3,463GBP
- Book
- June 2020
- 198 Pages
- Report
- November 2021
- 802 Pages
Global
From €4599EUR$5,000USD£3,891GBP
- Report
- November 2021
- 1184 Pages
Global
From €5518EUR$6,000USD£4,670GBP
- Book
- March 2024
- 544 Pages

Cell targeting is a biotechnology field that focuses on the development of treatments that target specific cells in the body. It involves the use of drugs, antibodies, and other molecules to target and interact with specific cells. This technology has been used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. It has also been used to deliver gene therapy and to develop vaccines.
Cell targeting is a rapidly growing field, with many companies investing in research and development. Companies are developing new technologies to improve the accuracy and efficiency of cell targeting, as well as to reduce the cost of treatments. These technologies include gene editing, nanotechnology, and artificial intelligence.
Some companies in the cell targeting market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more